UNSPSC 51372807: Quadazocine mesylate

This classification denotes an opioid receptor agonist and opiate antagonist with the molecular formula C25H37NO2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 582SS143QX, chemically known as 3-pentanone, 1-cyclopentyl-5-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)-, (2r-(2.alpha.,6.alpha.,11s*))-, methanesulfonate (salt), but more generally known as quadazocine mesylate, which bears US NIH Compound Identifier 3052769.

UNSPSC 51372807 Quadazocine mesylate is a Commodity code that nominally denotes a specific pharmaceutical substance, but recent state and local procurement activity under this code shows minimal direct alignment with the code's narrow chemical scope. The recent opportunities posted under this code actually solicit naloxone, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs — a divergence suggesting the code may be misapplied in state and local systems or serves as a catch-all filing mechanism for pharmaceutical procurement that does not neatly fit narrower chemical-compound codes. Issuing bodies have included county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other participating states). The scope of work spans pharmaceutical supply chain management, including direct procurement of specific drug products with mandated National Drug Codes (NDCs), quarterly or ongoing delivery logistics, compliance with cGMP and Drug Supply Chain Security Act (DSCSA) requirements, and wholesale-relationship management through authorized distributors.

Recent activity concentrates in the South and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (with response due July 26, 2023, an apparent date error in the source) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program intended to inform future formal procurement. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) on January 20, 2026 with a March 26, 2026 response deadline to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencara, Cardinal Health, and Morris & Dickson), with contract awards effective July 1, 2026. No specific budget or award value is disclosed across these opportunities; MMCAP requires a 3 percent administrative fee on all purchases and imposes performance penalties of $200 to $1,500 per violation. The code shows limited recent activity overall and poor alignment between its nominal scope and what is actually being procured.